重症肌无力
Myasthenia gravis
定义 英文原文（暂无中文）
A rare autoimmune disorder of the neuromuscular junction characterized by fatigable weakness of voluntary muscles.
别名
自身免疫性重症肌无力
基本事实
- 遗传方式
- 多基因/多因素、不适用
- 发病年龄
- 各年龄段
- 患病率
- 1-9 / 1 000 000（United States）
临床表型 45
极常见 99–80%1
- 肌无力 HP:0001324
常见 79–30%24
- 胸腺形态异常 HP:0000777
- 抗神经肌肉接头乙酰胆碱受体抗体阳性 HP:0030208
- 抗DCC netrin 1受体抗体阳性 HP:6000881
- 抗Kv1.4抗体 HP:5000048
- 抗兰尼碱受体抗体 HP:5000047
- 抗titin抗体阳性 HP:5000038
- 球麻痹 HP:0001283
- 爬楼梯困难 HP:0003551
- 复视 HP:0000651
- 构音障碍 HP:0001260
- 吞咽困难 HP:0002015
- 发音困难 HP:0001618
- 呼吸困难 HP:0002094
- 骨骼肌疲劳性无力 HP:0030197
- 疲乏 HP:0012378
- 四肢肌肉无力 HP:0003690
- 抗肌特异性酪氨酸激酶抗体 HP:0030210
- 肌炎 HP:0100614
- 眼肌瘫痪 HP:0000597
- 上睑下垂 HP:0000508
- 单纤维肌电图异常 HP:0030006
- 骨骼肌萎缩 HP:0003202
- 胸腺增生 HP:0010516
- 面部肌肉无力 HP:0030319
偶见 29–5%14
- 抗Lrp4抗体阳性 HP:5000046
- 糖尿 HP:0003076
- 桥本甲状腺炎 HP:0000872
- 听力受损 HP:0000365
- 听觉过敏 HP:0010780
- 甲状腺功能亢进症 HP:0000836
- 感觉异常 HP:0003401
- 原发性肾上腺功能不全 HP:0008207
- 雷诺现象 HP:0030880
- 呼吸衰竭 HP:0002878
- 类风湿关节炎 HP:0001370
- 系统性红斑狼疮 HP:0002725
- 胸腺瘤 HP:0100522
- 舌萎缩 HP:0012473
罕见 <4–1%6
- 手足发绀 HP:0001063
- 溶血性贫血 HP:0001878
- 肝炎 HP:0012115
- 精神病 HP:0000709
- 纯红细胞再生障碍性贫血 HP:0012410
- 癫痫发作 HP:0001250
近两年的全球研究 6,062L2
2024/08 起在 Europe PMC 检索所得，按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务，尚未引入。
- 2026-12Study on nutritional status and incidence of sarcopenia in elderly patients with chronic heart failure
- 2026-08Clinicopathological profile and treatment outcomes of advanced/unresectable thymic malignancies from a tertiary care centre in India
- 2026-08Rate of Autoimmune Diseases in the 10 Years Preceding Myasthenia Gravis Diagnosis: A Nationwide Cohort Study in South Korea
- 2026-08Intravenous methocarbamol for acute pain after spine surgery: a target trial emulation
- 2026-08Prospective study of efgartigimod in severe myasthenia gravis exacerbations requiring ventilatory or enteral support
- 2026-08Long-Term Cancer and Mortality After Thymectomy
- 2026-07High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies
- 2026-07Response to the comment on "Longitudinal MuSK antibody levels may correlate with disease severity in MuSK myasthenia gravis"
- 2026-07Comment on "Longitudinal MuSK antibody levels may correlate with disease severity in MuSK myasthenia gravis"
- 2026-07Identification of PTGS2 as a genetically supported protective biomarker and potential therapeutic target in myasthenia gravis
- 2026-07综述Pediatric Extrapolation in Neuropsychiatric Drug Development: Leveraging Pharmacokinetic and Pharmacodynamic Strategies to Facilitate FDA Approvals
- 2026-07Exploring the Value of Quantitative Muscle Ultrasound in Neuromuscular Junction Disorders: A Pilot Study
- 2026-07South African Flag Sign in Contrast-Induced Kounis Syndrome: When the Flag Misleads
- 2026-07Beyond muscle weakness: Expanding the therapeutic horizon of thymectomy in myasthenia gravis
- 2026-07Terminal complement inhibition is associated with renal, hematologic, and thrombotic complications during septic shock: A global propensity score-matched cohort study
- 2026-07综述CAR-based cellular therapies for autoimmune diseases: immune reset, clinical evidence, and translational boundaries
- 2026-07Postoperative Complications Following Spine Surgery in Myasthenia Gravis Patients: A Propensity-Matched National Database Analysis
- 2026-07Gefurulimab-The First Effective Nanobody in Myasthenia Gravis Therapy
- 2026-07Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial
- 2026-07Mismatch Between the Distribution of Neuromuscular Specialists and Myasthenia Gravis Patients in the US Medicare Fee-for-Service Population
国家医保药品目录中点名本病的药品 3L2
出自《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》（医保发〔2025〕33号，2026-01-01 起执行）。下列药品在药品名称或限定支付范围里出现了本病的名称。
匹配不到 ≠ 不能报销。目录里只有约一成药品设了限定支付范围，其余按适应症正常使用同样可报销；本区块只能回答「目录有没有点名这个病」，不能回答「这个病有没有药能报销」。各省执行细则、双通道与单独支付范围另有规定，请以当地医保部门口径为准。
- 依库珠单抗注射液乙类谈判药品限：1.阵发性睡眠性血红蛋白尿症(PNH)的患者；2.非典型溶血性尿毒症综合征(aHUS)的患者；3.抗乙酰胆碱受体(AChR)抗体阳性的难治性全身型重症肌无力(gMG)成人患者。
- 注射用泰它西普乙类谈判药品限：1.在常规治疗基础上仍具有高疾病活动(例如：抗ds-DNA抗体阳性及低补体、SELENA-SLEDAI评分≥8)的活动性、自身抗体阳性的系统性红斑狼疮(SLE)成年患者；2.抗乙酰胆碱受体(AChR)抗体阳性的成人全身型重症肌无力(gMG)患者。
- 艾加莫德α注射液乙类谈判药品限乙酰胆碱受体(AChR)抗体阳性的成人全身型重症肌无力(gMG)患者。
境外已获批用于本病的药物 13L2
欧盟 5 项、美国 8 项。同一药物在两地各批一次的，会分别列出。
「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径，各有各的条件与费用。这一节能确定地告诉你的只有一件事：这个病在世界范围内已经有获得批准的药物，它叫什么名字。拿这个名字去问主治医生，是下一步最省力的做法。
药名一律保留英文原文，不作翻译——中国的药品通用名与英文名的音译经常不一致，译错会让人去找一个不存在的药。
- Amifampridine SERB欧盟2022-05-19amifampridine官方记录
- Vyvgart欧盟2022-08-10efgartigimod alfa官方记录
- Zilbrysq欧盟2023-12-01zilucoplan官方记录
- Rystiggo欧盟2024-01-05rozanolixizumab官方记录
- Imaavy欧盟2025-11-28nipocalimab官方记录
- Soliris美国2017-10-23eculizumab官方记录
- Vyvgart美国2021-12-17efgartigimod alfa-fcab官方记录
- Ultomiris美国2022-04-27ravulizumab-cwvz官方记录
- Vyvgart Hytrulo美国2023-06-20efgartigimod alfa and hyaluronidase-qvfc官方记录
- Rystiggo美国2023-06-26rozanolixizumab-noli官方记录
- Zilbrysq美国2023-10-17zilucoplan官方记录
- Imaavy美国2025-04-29nipocalimab-aahu官方记录
- Uplizna美国2025-12-11inebilizumab-cdon官方记录
已获孤儿药资格、尚未获批的在研药物（31 项）
孤儿药资格只是一种监管身份——它意味着监管机构认可这是罕见病用药并给予研发激励，不代表这个药已被证明有效，也不代表将来一定能上市。绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
- Peptides mimicking antigen receptors on autoimmune B cells and autoimm欧盟2009-11-09Treatment of myasthenia gravis官方记录
- recombinant mutated extracellular domain of the human acetylcholine re欧盟2019-07-25Treatment of myasthenia gravis官方记录
- batoclimab欧盟2022-08-10Treatment of myasthenia gravis官方记录
- autologous T cells transduced with lentiviral vector containing a chim欧盟2025-02-20Treatment of myasthenia gravis官方记录
- telitacicept欧盟2025-07-18Treatment of myasthenia gravis官方记录
- Recombinant Human Alpha-Fetoprotein (rhAFP)美国2001-02-22Treatment of myasthenia gravis官方记录
- peptides mimicking antigen receptors on autoimmune B cells and autoimm美国2011-02-04Treatment of myasthenia gravis官方记录
- neostigmine methylsulfate美国2012-02-17Treatment of Myasthenia Gravis官方记录
- Methotrexate美国2014-08-28Treatment of Myasthenia Gravis官方记录
- immune globulin (human)美国2016-12-12Treatment of Myasthenia Gravis官方记录
- Mutated form of human acetylcholine receptor a1 extracellular domain s美国2017-03-16Treatment of myasthenia gravis官方记录
- Fully human anti-human neonatal Fc receptor (hFcRn) IgG1 monoclonal an美国2021-06-24Treatment of Myasthenia Gravis官方记录
- Rituximab美国2021-10-12Treatment of Myasthenia Gravis官方记录
- bromophenoxyazole propanoic acid美国2022-09-12Treatment of Myasthenia Gravis官方记录
- telitacicept美国2022-09-27Treatment of Myasthenia Gravis官方记录
- autologous Muscle-Specific tyrosine Kinase Autoantibody Receptor T cel美国2022-10-07Treatment of muscle-specific tyrosine kinase (MuSK) myasthenia gravis官方记录
- Mezagitamab美国2022-10-17Treatment of myasthenia gravis官方记录
- autologous T-cells expressing a chimeric antigen receptor directed aga美国2022-11-08Treatment of Myasthenia Gravis官方记录
- Immunoglobulin G [27-histidine,57-histidine,253-tyrosine,255- threonin美国2022-11-08Treatment of myasthenia gravis官方记录
- cladribine美国2023-06-14Treatment of myasthenia gravis官方记录
- cemdisiran美国2023-07-05Treatment of Myasthenia Gravis (MG)官方记录
- gefurulimab美国2023-08-03treatment of myasthenia gravis官方记录
- pozelimab and cemdisiran combiantion美国2023-08-28Treatment of myasthenia gravis官方记录
- (-)-Huperzine A美国2023-12-12Treatment of Myasthenia Gravis官方记录
- prednisone美国2024-03-12Treatment of Myasthenia Gravis官方记录
- autologous anti-CD19 CAR T cell immunotherapy美国2024-04-24treatment of myasthenia gravis官方记录
- composed of seven antigenic peptides derived from the acetylcholine re美国2025-09-12treatment of myasthenia gravis (MG)官方记录
- resecabtagene autoleucel美国2025-12-10treatment of myasthenia gravis官方记录
- iptacopan美国2025-12-19treatment of myasthenia gravis官方记录
- povetacicept美国2026-02-02treatment of myasthenia gravis官方记录
- claseprubart美国2026-05-01treatment of myasthenia gravis官方记录
数据来自欧洲药品管理局（EMA）的药品与孤儿药资格公开导出表，以及美国 FDA 孤儿药资格数据库。两边口径不同：欧盟一侧取的是当前状态仍为「已授权」的药品；美国一侧记录的是「曾获批准」这一事实，FDA 的公开表不追踪药物此后是否退市（例如 Relyvrio 于 2024 年撤市，表中仍记为已获批）。请以官方记录页为准。
在中国开展的临床试验 88L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实，并与主治医生商量。
登记为可入组 44
- 招募中NCT04182984TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study中国研究中心 1 个：Xi'an
- 招募中NCT04202341Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)中国研究中心 8 个：Beijing、Changchun、Chengdu、Guangzhou、Jinan、Nanchang 等 8 地
- 招募中NCT04561557Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System中国研究中心 1 个：Wuhan
- 招募中NCT04837625Study of Myasthenic Crisis in China中国研究中心 1 个：Shanghai
- 招募中NCT04951622A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis中国研究中心 14 个：Beijing、Changchun、Changsha、Chengdu、Fuzhou、Guangzhou 等 11 地
- 招募中NCT05067348Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis中国研究中心 6 个：Beijing、Changsha、Chengdu、Shanghai、Tianjin、Xi'an
- 招募中NCT06006832A Prospective Cohort Study of Myasthenia Gravis in China中国研究中心 1 个：Beijing
- 招募中NCT07146425Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis中国研究中心 1 个：Shanghai
- 招募中NCT04535843Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China中国研究中心 4 个：Shanghai
- 招募中NCT06241521Myasthenia Gravis Registry in China中国研究中心 16 个：Beijing、Changchun、Changsha、Chengdu、Chongqing、Guangzhou 等 13 地
- 招募中NCT06249438A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy中国研究中心 1 个：Shanghai
- 招募中NCT07653984Cohort Study on Neuroimmune Diseases in the Reproductive Age中国研究中心 1 个：Guangzhou
- 招募中NCT06463587Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)中国研究中心 15 个：Anhui Sheng、Beijing、Changchun、Changsha、Chengdu、Guangzhou 等 13 地
- 招募中NCT06447597A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.中国研究中心 18 个：Beijing、Changchun、Changsha、Chengdu、Guangzhou、Hangzhou 等 15 地
- 招募中NCT06371040Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis中国研究中心 1 个：Xi'an
- 招募中NCT06456580A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)中国研究中心 19 个：Beijing、Changchun、Changsha、Chongqing、Fuzhou、Guangzhou 等 17 地
- 招募中NCT06502015Biomarkers in Autoimmune Disease of Nervous System中国研究中心 1 个：Wuhan
- 招募中NCT06744920A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis中国研究中心 10 个：Beijing、Changchun、Guangzhou、Hefei、Qingdao、Shanghai 等 10 地
- 尚未开始招募NCT06759948An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis中国研究中心 1 个：Shanghai
- 尚未开始招募NCT06485232Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.中国研究中心 1 个：Beijing
- 招募中NCT06688435A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis中国研究中心 1 个：Jinan
- 尚未开始招募NCT06933563UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis中国研究中心 1 个：Hangzhou
- 招募中NCT07022197Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases中国研究中心 1 个：Tianjin
- 尚未开始招募NCT06978738UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases中国研究中心 1 个：Changzhou
- 招募中NCT06939166Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases中国研究中心 1 个：Tianjin
另有 19 项未列出。
其他状态的试验（44 项）
- 已完成NCT01325571A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis中国研究中心 9 个：Beijing、Guangdong、Jiangsu、Jilin City、Shandong、Shanghai 等 9 地
- 已完成NCT01727193The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy中国研究中心 1 个：Guangzhou
- 状态未知NCT02317224The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor中国研究中心 1 个：Xi'an
- 状态未知NCT03597373Variables Predicting Reintubation After Thymectomy in Patients With Myasthenia Gravis中国研究中心 1 个：Guangzhou
- 状态未知NCT04101578Clinical Prognosis and Progression of Myasthenia Gravis Patients中国研究中心 1 个：Beijing
- 已完成NCT05380128Association Study Between VDR Gene Polymorphisms and Risk and Features of MG in Han Chinese Population中国研究中心 1 个：Beijing
- 状态未知NCT03613272The Curative Effect of Extended Thymectomy Performed Through Subxiphoid-right VATS Approach With Elevation of Sternum中国研究中心 5 个：Haikou、Shanghai、Shaoxing、Taiyuan、Taizhou
- 已完成NCT04431895Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study中国研究中心 1 个：Shanghai
- 已完成NCT04302103A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis中国研究中心 24 个：Beijing、Bengbu、Changchun、Changsha、Chengdu、Chongqing 等 20 地
- 已完成NCT04346888A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients中国研究中心 1 个：Shanghai
- 状态未知NCT05332587Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis中国研究中心 1 个：Guangzhou
- 进行中·不再招募NCT04524273Myasthenia Gravis Inebilizumab Trial中国研究中心 10 个：Beijing、Guiyang、Hunan、Jinan、Shanghai、Suzhou 等 8 地
- 状态未知NCT06443333National, Multicentric Registry Study on Neuroimmunological Diseases in China中国研究中心 1 个：Beijing
- 状态未知NCT04674605A Prospective Cohort Study Of Myasthenia Gravis中国研究中心 1 个：Chongqing
- 状态未知NCT05091177Study on Correlation Between Cytomegalovirus and Ocular Myasthenia Gravis中国研究中心 1 个：Guangzhou
- 已完成NCT05219097The Specificity, Sensitivity and Clinical Correlation of CBA, RIPA and ELISA in Detecting AChR and MuSK IgG of Myasthenia Gravis中国研究中心 2 个：Beijing、Tianjin
- 状态未知NCT04768465Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia Gravis中国研究中心 1 个：Beijing
- 已完成NCT05024071Effect of Core Strength Training on Wushu C-level Difficulty Movements ,12 Weeks of Core Strength Training中国研究中心 1 个：Yinchuan
- 已完成NCT05039190Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients中国研究中心 1 个：Shanghai
- 已终止NCT04963270A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis中国研究中心 12 个：Beijing、Changchun、Chengdu、Guiyang、Hangzhou、Jinan 等 10 地
- 已终止NCT05132569Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis中国研究中心 3 个：Chengdu、Shanghai、Wuhan
- 进行中·不再招募NCT05070858A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis中国研究中心 15 个：Beijing、Changchun、Changsha、Chengdu、Fuzhou、Guangdong 等 14 地
- 状态未知NCT05248568Effect of Core Training on Physical Fitness and Offensive Skills, 12 Weeks Core Training中国研究中心 1 个：Wuhan
- 状态未知NCT05262582Comparison of Single Port and Two Ports Robotic Assisted Thoracic Surgery for Thymectomy中国研究中心 1 个：Shanghai
- 已完成NCT05332210Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis中国研究中心 1 个：Shanghai
- 进行中·不再招募NCT07071246Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis中国研究中心 1 个：Xi'an
- 进行中·不再招募NCT05556096Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis中国研究中心 12 个：Beijing、Changchun、Changsha、Chengdu、Fuzhou、Hangzhou 等 12 地
- 已完成NCT05737160Study of Telitacicept in Generalized Myasthenia Gravis中国研究中心 51 个：Beijing、Bengbu、Changchun、Changsha、Chengdu、Dalian 等 33 地
- 状态未知NCT05716035Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis中国研究中心 6 个：Beijing、Changsha、Chengdu、Shanghai、Tianjin、Xi'an
- 状态未知NCT05828225Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis中国研究中心 1 个：Hangzhou
- 状态未知NCT05888558Screening of Serum Exosomal miRNA as a Biomarker for Ocular Muscle Myasthenia Gravis中国研究中心 1 个：Guangzhou
- 已完成NCT07154095A Single-Center, Randomized, Open-Label, Two-Sequence, Two-Period, Crossover Study Comparing the Pharmacokinetics and Safety of Pyridostigmine Sustained-Release and Immediate-Release Tablets Following Single and Multiple Doses in Healthy Chinese Participants中国研究中心 1 个：Chengdu
- 已完成NCT07472777Long-term Efficacy of Modified Guilu Erxian Glue for Myasthenia Gravis中国研究中心 1 个：Zhengzhou
- 进行中·不再招募NCT06298552A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis中国研究中心 14 个：Beijing、Changchun、Chongqing、Fuzhou、Guangxi、Guangzhou 等 12 地
- 已完成NCT06436768Efficacy and Safety of Sugammadex in Thoracoscopy Thymectomy for Chinese Adults With Myasthenia Gravis中国研究中心 2 个：Beijing、Nanjing
- 进行中·不再招募NCT06707727Characteristics and Prognostic Outcomes of Diaphragmatic Ultrasound in Myasthenia Gravis中国研究中心 1 个：Chongqing
- 进行中·不再招募NCT06517758A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.中国研究中心 11 个：Beijing、Changsha、Fujian、Guangzhou、Hefei、Jinan 等 11 地
- 进行中·不再招募NCT06558279A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis中国研究中心 12 个：Changsha、Chengdu、Chongqing、Fuzhou、Guangzhou、Jinan 等 10 地
- 进行中·不再招募NCT06700616A Study in Patients With Myasthenia Gravis in China中国研究中心 20 个：Beijing、Chengdu、Fuzhou、Guangzhou、Guiyang、Harbin 等 20 地
- 已撤回NCT06419166An Exploratory Clinical Study of GC012F Injection for Refractory gMG中国研究中心 1 个：Hanzhou
另有 4 项未列出。
中国境外的在招试验 135L2
这些试验在中国没有研究中心，通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处：看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生，或据此进一步查该药是否已在境外获批、是否有拓展性用药（expanded access）通道。
美国49意大利21法国15波兰14西班牙11英国11德国10比利时7加拿大6日本6澳大利亚5荷兰5塞尔维亚4以色列4另有 17 个国家/地区
CT.gov 报告命中 135 项，此处取回并展示最近的 15 项。
- 尚未开始招募NCT07571525Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis意大利
- 招募中NCT06987539A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)法国、西班牙、英国、美国
- 招募中NCT07673744A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)美国
- 尚未开始招募NCT07677852Sexual and Urinary Dysfunctions in Generalized Myasthenia法国
- 尚未开始招募NCT07465289A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- 招募中NCT07673627ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis美国
- 招募中NCT07647510A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)美国
- 招募中NCT07570589Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)法国
- 招募中NCT07717281PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis意大利
- 招募中NCT07463521A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis美国
- 招募中NCT07501702A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis澳大利亚、波兰、英国、美国
- 招募中NCT07596901Study of Aritinercept in Patients With Generalized Myasthenia Gravis美国
- 招募中NCT07304154A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases澳大利亚、加拿大、美国
- 招募中NCT06866652Evaluating Dyspnea in Autoimmune Myasthenia Gravis "Why am I Short of Breath?"法国
- 尚未开始招募NCT07323316Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
外部标识与链接
OrphanetOMIM:159400OMIM:254200OMIM:607085MONDO:0009688GARD:7122ICD-10 G70.0ICD-11 8C60ClinicalTrials.gov 检索
发现这一页有错误？告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学：Orphanet（CC BY 4.0）
- 中文病名：Orphanet 中文包，冻结于 2020-06-01
- 表型中文标签：HPO 简体中文翻译（CHPO 上游成果）